133 STAT. 946  PUBLIC LAW 116–22—JUNE 24, 2019  ‘‘(I) ensure that each countermeasure or product under  consideration for procurement pursuant to this subsection  receives the same consideration regardless of whether such  countermeasure or product receives or had received funding  under section 319L, including with respect to whether the  countermeasure or product is most appropriate to meet  the emergency health security needs of the United States;  and  ‘‘(J) provide assistance, including technical assistance,  to maintain and improve State and local public health  preparedness capabilities to distribute and dispense med- ical countermeasures and products from the stockpile, as  appropriate.’’; and  (5) by adding at the end the following:  ‘‘(5) GAO REPORT.—  Deadline.  Time period.  Review.  Assessments.  ‘‘(A) IN GENERAL.—Not later than 3 years after the  date of enactment of the Pandemic and All-Hazards  Preparedness and Advancing Innovation Act of 2019, and  every 5 years thereafter, the Comptroller General of the  United States shall conduct a review of any changes to  the contents or management of the stockpile since January  1, 2015. Such review shall include—  ‘‘(i) an assessment of the comprehensiveness and  completeness of each annual threat-based review under  paragraph (2), including whether all newly procured  or replenished countermeasures within the stockpile  were described in each annual review, and whether,  consistent with paragraph (2)(B), the Secretary con- ducted the necessary internal review in advance of  such procurement or replenishment;  ‘‘(ii) an assessment of whether the Secretary estab- lished health security and science-based justifications,  and a description of such justifications for procurement  decisions related to health security needs with respect  to the identified threat, for additions or modifications  to the stockpile based on the information provided  in such reviews under paragraph (2)(B), including  whether such review was conducted prior to procure- ment, modification, or replenishment;  ‘‘(iii) an assessment of the plans developed by the  Secretary for the deployment, distribution, and dis- pensing of countermeasures procured, modified, or  replenished under paragraph (1), including whether  such plans were developed prior to procurement, modi- fication, or replenishment;  ‘‘(iv) an accounting of countermeasures procured,  modified, or replenished under paragraph (1) that  received advanced research and development funding  from the Biomedical Advanced Research and Develop- ment Authority;  ‘‘(v) an analysis of how such procurement decisions  made progress toward meeting emergency health secu- rity needs related to the identified threats for counter- measures added, modified, or replenished under para- graph (1);  ‘‘(vi) a description of the resources expended  related to the procurement of countermeasures  Analysis. 